BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable sal...

Full description

Saved in:
Bibliographic Details
Main Authors VENKATESHAPPA Chandregowda, PENDYALA Muralidhar, SIVANANDHAN Dhanalakshmi, RAJAGOPAL Sridharan, D A Jeyaraj
Format Patent
LanguageEnglish
Spanish
Published 20.01.2021
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation. Los compuestos de Fórmula I se describe en el presente documento junto con sus polimorfos, estereoisómeros, tautómeros, profármacos, solvatos y sales farmacéuticamente aceptables de los mismos. Los compuestos que se describen en el presente documento, sus polimorfos, estereoisómeros, tautómeros, profármacos, solvatos y sales farmacéuticamente aceptables de los mismos son compuestos bicíclicos que son inhibidores de la interacción/activación de PD-1/PD-L1. (Ver Fórmula I).
Bibliography:Application Number: MX20200009517